Skip to main content
. 2025 Jan 7;51(1):106–114. doi: 10.1007/s00134-024-07758-0

Table 1.

Patient´s baseline characteristics

Entire population
n = 2341
Successfully extubated
n = 1936
Reintubated
n = 405
p
General characteristics
 Male, n (%) 1433 1170 (60.4) 263 (64.9) 0.361
 Age, mean (± SD) 60 (20.0) 60 (20.0) 62 (19.0) 0.004
 APACHE II at ICU admission, mean (± SD)a 16 (6.0) 16 (6.0) 18 (8.0)  < 0.001
 SARS COVID-19, no. (%)b 334 274 (14.2) 60 (14.8) 0.789
High risk factors for extubation failure, no. (%)c
 Hypercapnia at the end of the SBT 127 86 (4.4) 41 (10.1)  < 0.001
 Airway patency problems 140 109 (0.1) 31 (7.6) 0.148
 Respiratory secretions 332 248 (12.8) 84 (20.7)  < 0.001
 Not simple weaning 602 446 (23.0) 156 (38.5)  < 0.001
 APACHE II > 12 at extubationa 493 358 (18.5) 135 (33.3)  < 0.001
 BMI > 30d 379 272 (14.0) 107 (26.4)  < 0.001
 CHARLSON index ≥ 2e 963 764 (39.5) 199 (10.3)  < 0.001
 Prolonged mechanical ventilation 584 446 (23.0) 138 (34.1)  < 0.001
 Acute cardiac failure 190 138 (7.1) 52 (12.8) 0.001
 At least moderate COPD 239 179 (9.2) 60 (14.8) 0.001
 Age > 65 y 713 572 (29.5) 141 (34.8) 0.042
Comorbidities, no. (%)e
 Chronic heart disease 489 401 (20.7) 88 (21.7) 0.697
 COPD 241 190 (9.8) 51 (12.6) 0.113
 Other respiratory diseases 561 449 (23.2) 112 (27.6) 0.064
 Vascular diseases 114 84 (4.3) 30 (7.4) 0.013
 Hepatic diseases 175 125 (6.5) 50 (12.3)  < 0.001
 Other diseases 324 254 (13.1) 70 (17.3) 0.033
Diagnosis at ICU admission, no. (%)g
 Primary respiratory failure 1346 1092 (56.4) 254 (62.7) 0.023
 Primary non-respiratory failure 1376 1150 (59.4) 226 (55.8) 0.200
 Trauma 294 243 (12.5) 51 (12.6) 1
 Surgical procedure 781 656 (33.9) 125 (30.8) 0.265
Screening strategy, no. (%)f
 Conservative strategy 1980 1633 (84.3) 347 (85.7) 0.533
 Aggressive strategy 361 303 (15.6) 58 (14.3)
SBT, no. (%)
 T-tube trial 382 345 (17.8) 37 (9.1)  < 0.001
 Pressure support 5 cm H2O 517 445 (22.9) 72 (17.8)
 Pressure support 7 cm H2O 1075 843 (43.5) 232 (57.3)
 Pressure support 8 + PEEP 5 cm H2O 367 304 (15.7) 63 (15.6)
Postextubation preventive therapy, no. (%)
 COT 263 231 (11.9) 32 (7.9) 0.015
 HFNC 1600 1325 (68.4) 275 (68.0)
 NIV 478 380 (19.6) 98 (24.2)
Three factors model predicting extubation failure, no. (%)
 Low risk patients 1016 866 (44.7) 150 (37.0) 0.007
 High risk patients 1325 1070 (55.3) 255 (63.0)
Four factors model predicting extubation failure, no. (%)
 Low risk patients 802 702 (36.3) 100 (24.7)  < 0.001
 High risk patients 1539 1234 (63.7) 305 (75.3)
Eleven factors model predicting extubation failure, no. (%)
 Low risk patients 673 609 (31.5) 64 (15.8)  < 0.001
 High risk patients 1668 1327 (68.5) 341 (84.2)

APACHE II Acute Physiology and Chronic Health Evaluation II; BMI body mass index; COPD chronic obstructive pulmonary disease; COT conventional oxygen therapy; HFNC high flow nasal cannula; NIV noninvasive ventilation; PEEP positive end-expiratory pressure; SARS COVID-19 severe acute respiratory syndrome secondary to coronavirus disease 2019; SBT spontaneous breathing trial

aAPACHE II score was calculated from 17 variables. Scores range from 0 to 71 points, with higher scores indicating more severe disease

bSevere hypoxemic respiratory failure secondary to RT-PCR-confirmed COVID-19 pneumonia

cDefined according to references [12, 13]

dBody mass index calculated as weight in kilograms divided by height in meters squared

eComorbidities were categorized based on the Charlson Comorbidity Index (detailed in the online supplement). Fully detailed in Table S1

fScreening strategy defined according to the protocol reported in reference [8]

gThere can be more than one diagnosis